Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

Memorial Sloan Kettering Cancer Center

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1884-01-01

Employees: 10K

Market Cap: -

Website: http://www.mskcc.org

Clinical Trials

A Study of Nivolumab In Combination With Cabozantinib in Patients With Non-Clear Cell Renal Cell Carcinoma

Phase 2

Active, not recruiting

Conditions: Advanced or Metastatic Non-clear Cell Renal Cell Carcinoma
Unclassified Renal Cell Carcinoma
Papillary Renal Cell Carcinoma
Fumarate Hydratase Deficient Renal Cell Carcinoma
Succinate Dehydrogenase Deficient Renal Cell Carcinoma
Collecting Duct Renal Cell Carcinoma
Chromophobe Renal Cell Carcinoma

Interventions: Drug: cabozantinib
Drug: nivolumab

First Posted Date: 2018-08-17

Last Posted Date: 2024-05-22

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 60

Registration Number: NCT03635892

Locations: 🇺🇸
Memorial Sloan Kettering Basking Ridge, Basking Ridge, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Commack, Commack, New York, United States
🇺🇸
Memorial Sloan Kettering Monmouth, Middletown, New Jersey, United States

and more 4 locations

Imaging With a PET Agent for Detection of Cancers of the Head and Neck

Phase 1

Recruiting

Conditions: Head and Neck Cancer

Interventions: Drug: [18F]- PARPi
Diagnostic Test: PET/CT Scans

First Posted Date: 2018-08-15

Last Posted Date: 2025-01-13

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 27

Registration Number: NCT03631017

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

Ixazomib Maintenance Study in Patients With AL Amyloidosis

Phase 2

Active, not recruiting

Conditions: AL Amyloidosis

Interventions: Drug: Ixazomib
Drug: Dexamethasone

First Posted Date: 2018-08-07

Last Posted Date: 2024-12-04

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 17

Registration Number: NCT03618537

Locations: 🇺🇸
Memorial Sloan Kettering Nassau, Uniondale, New York, United States
🇺🇸
Tufts Medical Center, Boston, Massachusetts, United States
🇺🇸
Memorial Sloan Kettering Monmouth, Middletown, New Jersey, United States

and more 5 locations

Phase II Study of Second- Line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin Lymphoma

Phase 2

Recruiting

Conditions: Hodgkin Lymphoma
Relapsed or Refractory Hodgkin Lymphoma

Interventions: Drug: pembrolizumab
Drug: gemcitabine
Drug: vinorelbine
Drug: liposomal doxorubicin
Procedure: Stem cell mobilization and collection

First Posted Date: 2018-08-07

Last Posted Date: 2025-06-04

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 257

Registration Number: NCT03618550

Locations: 🇺🇸
University of Miami, Miami, Florida, United States
🇺🇸
Memorial Sloan Kettering Basking Ridge, Basking Ridge, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Monmouth, Middletown, New Jersey, United States

and more 5 locations

Assessment of Sensory Gating, Attention, and Executive Control in Breast Cancer

Active, not recruiting

Conditions: Breast Cancer

Interventions: Other: SAE battery
Behavioral: Assessments

First Posted Date: 2018-08-07

Last Posted Date: 2025-01-09

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 187

Registration Number: NCT03619083

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

Treatment of Tumors in the Urinary Collecting System of the Kidney or Ureter Using a Light Activated Drug (WST11)

Phase 1

Active, not recruiting

Conditions: Upper Tract Urothelial Carcinoma

Interventions: Drug: WST11 mediated vascular targeted phototherapy (VTP)
Procedure: Endoscopy

First Posted Date: 2018-08-06

Last Posted Date: 2024-12-16

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 30

Registration Number: NCT03617003

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

TCR Alpha Beta T-cell and CD19 B-cell Depleted Peripheral Blood Stem Cell Transplantation Using the CliniMACS System for Patients With Non-Malignant Hematologic Disorders From Matched or Mismatched, Related or Unrelated Donors

Phase 2

Terminated

Conditions: Non-Malignant Hematologic Disorders

Interventions: Drug: Melphalan
Drug: Thiotepa
Drug: Clofarabine
Drug: Fludarabine
Drug: Anti-Thymocyte Globulin (Rabbit) (Thymoglobulin®)
Procedure: CliniMACS reagents

First Posted Date: 2018-08-03

Last Posted Date: 2021-03-24

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 1

Registration Number: NCT03615144

Locations: 🇺🇸
Memorial SloanKettering Cancer Center, New York, New York, United States

Donor Stem Cell Transplantation Using α/β+ T-lymphocyte Depleted Grafts From HLA Mismatched Donors

Phase 2

Terminated

Conditions: Non-Hodgkin Lymphoma
Chronic Lymphocytic Leukemia
Acute Lymphoid Leukemia (ALL)
Chronic Myeloid Leukemia (CML)
Hodgkin Lymphoma
Acute Myeloid Leukemia (AML)

Interventions: Radiation: Hyperfractionated total body irradiation
Drug: Busulfan
Drug: Thiotepa
Drug: Fludarabine
Drug: Melphalan
Drug: Cyclophosphamide
Drug: Clofarabine
Procedure: HPC(A) stem cell allograft
Drug: Rituximab
Device: Rabbit antithymocyte globulin

First Posted Date: 2018-08-03

Last Posted Date: 2025-04-06

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 9

Registration Number: NCT03615105

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

Evaluation of Preoperative Functional Magnetic Resonance Imaging (fMRI) in Patients With Brain Tumors

Not Applicable

Active, not recruiting

Conditions: Brain Tumor

Interventions: Device: fMRI Paradigms

First Posted Date: 2018-07-27

Last Posted Date: 2025-01-23

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 33

Registration Number: NCT03604302

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

A Study of the Effect of Blood Stem Cell Transplant After Chemotherapy Alone in Patients With Fanconi Anemia

Phase 2

Terminated

Conditions: Myelodysplastic Syndrome (MDS)
Acute Myelogenous Leukemia (AML)
Fanconi Anemia

Interventions: Drug: Busulfan
Drug: Fludarabine
Drug: Cyclophosphamide
Drug: Anti-Thymocyte Globulin (Rabbit)
Device: The CliniMACS device
Drug: G-CSF

First Posted Date: 2018-07-26

Last Posted Date: 2022-04-12

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 3

Registration Number: NCT03600909

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸
Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy